
Opinion|Videos|April 1, 2024
Treatment Goals and Options for Chronic GvHD
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Exploring the main treatment goals and current first-line and second-line treatment options for patients with chronic GvHD.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5

























